Stock Track | AKESO Plummets 5.03% Intraday on Disappointing Ivonescimab Phase III Interim Results
Stock Track
May 28
AKESO's stock plummeted 5.03% during intraday trading on Thursday, reflecting a significant negative market reaction.
The sharp decline is attributed to the market digesting disappointing interim results from the HARMONi-3 global pivotal Phase III study for the company's core product, ivonescimab. The study's squamous cell carcinoma cohort, targeting the first-line treatment of metastatic non-small cell lung cancer, failed to meet the pre-specified statistical significance threshold for progression-free survival. This outcome has raised investor concerns over whether the strong clinical data previously observed in Chinese populations can be successfully replicated on a global scale.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.